<DOC>
	<DOCNO>NCT00556959</DOCNO>
	<brief_summary>The purpose study determine whether CLONICEL® ( clonidine HCl sustain release ) safe effective treatment child adolescent attention deficit hyperactivity disorder ( ADHD ) .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy CLONICEL® Treat Children Adolescents With Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description>Clonidine centrally act alpha2 adrenergic agonist use effectively since early 70 treat mild moderate hypertension . In addition hypertension , clonidine evaluate use extensively several indication , include attention deficit hyperactivity disorder ( ADHD ) . An easy administer clonidine formulation need retains efficacy current oral formulation improve safety profile . The current trial investigate safety efficacy clonidine deliver sustained release formulation CLONICEL treatment child adolescent ADHD .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Male female 6 17 year age , inclusive Diagnosis ADHD hyperactive combine inattentive/hyperactive subtypes accord DSMIV criterion Minimum score 26 ADHDRSIV questionnaire Baseline General good health judge Principal Investigator Body mass index ≥ 5th percentile subject 's age group accord CDC growth chart . Ability swallow tablet General IQ ≥80 judge Principal Investigator Subject well parent/guardian able sign inform assent consent form . If female childbearing potential , pregnant lactate agree use medically acceptable form birth control , hormonal medication , doublebarrier method , IUD Presence clinically significant illness abnormality physical examination clinical laboratory evaluation , opinion investigator , would increase safety risk clonidine administration interfere ability patient take part study . Presence clinically significant abnormality centrally interpret Electrocardiogram ( ECG ) read History presence concomitant psychiatric disorder require psychotropic medication severe concomitant Axis I Axis II disorder could interfere study assessment judgment Principal Investigator History concomitant conduct disorder ( CD ) History seizure , except single episode febrile seizure prior age 2 History syncopal episode Presence disorder would interfere absorption , metabolism , excretion clonidine History intolerance clonidine , include dermatologic reaction transdermal clonidine Presence history alcohol drug abuse Positive drug screen , exception ADHD drug Use investigational drug within 30 day study start .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Clonidine</keyword>
	<keyword>Attention Deficit</keyword>
	<keyword>Hyperactivity</keyword>
	<keyword>CLONICEL</keyword>
	<keyword>Addrenex</keyword>
</DOC>